The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β. The gene discussed is TGFB1; the disease is hereditary clear cell renal cell carcinoma.